A new strategy to control and eradicate “undruggable” oncogenic K-RAS-driven pancreatic cancer

Molecular insights and core principles learned from developmental and evolutionary biology

Robert E. Van Sciver, Michael P. Lee, Caroline Dasom Lee, Alex C. Lafever, Elizaveta Svyatova, Kevin Kanda, Amber L. Colliver, Lauren L. Siewertsz Van Reesema, Angela M. Tang-Tan, Vasilena Zheleva, Monicah N. Bwayi, Minglei Bian, Rebecca L. Schmidt, Lynn M. Matrisian, Gloria M Petersen, Amy H. Tang

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Oncogenic K-RAS mutations are found in virtually all pancreatic cancers, making K-RAS one of the most targeted oncoproteins for drug development in cancer therapies. Despite intense research efforts over the past three decades, oncogenic K-RAS has remained largely “undruggable”. Rather than targeting an upstream component of the RAS signaling pathway (i.e., EGFR/HER2) and/or the midstream effector kinases (i.e., RAF/MEK/ERK/PI3K/mTOR), we propose an alternative strategy to control oncogenic K-RAS signal by targeting its most downstream signaling module, Seven-In-Absentia Homolog (SIAH). SIAH E3 ligase controls the signal output of oncogenic K-RAS hyperactivation that drives unchecked cell proliferation, uncontrolled tumor growth, and rapid cancer cell dissemination in human pancreatic cancer. Therefore, SIAH is an ideal therapeutic target as it is an extraordinarily conserved downstream signaling gatekeeper indispensable for proper RAS signaling. Guided by molecular insights and core principles obtained from developmental and evolutionary biology, we propose an anti-SIAH-centered anti-K-RAS strategy as a logical and alternative anticancer strategy to dampen uncontrolled K-RAS hyperactivation and halt tumor growth and metastasis in pancreatic cancer. The clinical utility of developing SIAH as both a tumor-specific and therapy-responsive biomarker, as well as a viable anti-K-RAS drug target, is logically simple and conceptually innovative. SIAH clearly constitutes a major tumor vulnerability and K-RAS signaling bottleneck in pancreatic ductal adenocarcinoma (PDAC). Given the high degree of evolutionary conservation in the K-RAS/SIAH signaling pathway, an anti-SIAH-based anti-PDAC therapy will synergize with covalent K-RAS inhibitors and direct K-RAS targeted initiatives to control and eradicate pancreatic cancer in the future.

Original languageEnglish (US)
Article number142
JournalCancers
Volume10
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Developmental Biology
Pancreatic Neoplasms
Neoplasms
Adenocarcinoma
Ubiquitin-Protein Ligases
Oncogene Proteins
Mitogen-Activated Protein Kinase Kinases
Therapeutics
Growth
Phosphatidylinositol 3-Kinases
Pharmaceutical Preparations
Phosphotransferases
Biomarkers
Cell Proliferation
Neoplasm Metastasis
Mutation
Research

Keywords

  • Evolutionary conservation
  • Oncogenic K-RAS mutations
  • Oncogenic K-RAS pathway activation
  • Oncogenic K-RAS-driven tumor relapse and metastasis
  • Pancreatic tumor vulnerability
  • Signaling gatekeeper
  • SINA and SIAH family of RING domain E3 ligases
  • Ubiquitin-mediated proteolysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A new strategy to control and eradicate “undruggable” oncogenic K-RAS-driven pancreatic cancer : Molecular insights and core principles learned from developmental and evolutionary biology. / Van Sciver, Robert E.; Lee, Michael P.; Lee, Caroline Dasom; Lafever, Alex C.; Svyatova, Elizaveta; Kanda, Kevin; Colliver, Amber L.; Siewertsz Van Reesema, Lauren L.; Tang-Tan, Angela M.; Zheleva, Vasilena; Bwayi, Monicah N.; Bian, Minglei; Schmidt, Rebecca L.; Matrisian, Lynn M.; Petersen, Gloria M; Tang, Amy H.

In: Cancers, Vol. 10, No. 5, 142, 01.05.2018.

Research output: Contribution to journalReview article

Van Sciver, RE, Lee, MP, Lee, CD, Lafever, AC, Svyatova, E, Kanda, K, Colliver, AL, Siewertsz Van Reesema, LL, Tang-Tan, AM, Zheleva, V, Bwayi, MN, Bian, M, Schmidt, RL, Matrisian, LM, Petersen, GM & Tang, AH 2018, 'A new strategy to control and eradicate “undruggable” oncogenic K-RAS-driven pancreatic cancer: Molecular insights and core principles learned from developmental and evolutionary biology', Cancers, vol. 10, no. 5, 142. https://doi.org/10.3390/cancers10050142
Van Sciver, Robert E. ; Lee, Michael P. ; Lee, Caroline Dasom ; Lafever, Alex C. ; Svyatova, Elizaveta ; Kanda, Kevin ; Colliver, Amber L. ; Siewertsz Van Reesema, Lauren L. ; Tang-Tan, Angela M. ; Zheleva, Vasilena ; Bwayi, Monicah N. ; Bian, Minglei ; Schmidt, Rebecca L. ; Matrisian, Lynn M. ; Petersen, Gloria M ; Tang, Amy H. / A new strategy to control and eradicate “undruggable” oncogenic K-RAS-driven pancreatic cancer : Molecular insights and core principles learned from developmental and evolutionary biology. In: Cancers. 2018 ; Vol. 10, No. 5.
@article{4429e9d1ff324ad5a96e0302b6f12bc1,
title = "A new strategy to control and eradicate “undruggable” oncogenic K-RAS-driven pancreatic cancer: Molecular insights and core principles learned from developmental and evolutionary biology",
abstract = "Oncogenic K-RAS mutations are found in virtually all pancreatic cancers, making K-RAS one of the most targeted oncoproteins for drug development in cancer therapies. Despite intense research efforts over the past three decades, oncogenic K-RAS has remained largely “undruggable”. Rather than targeting an upstream component of the RAS signaling pathway (i.e., EGFR/HER2) and/or the midstream effector kinases (i.e., RAF/MEK/ERK/PI3K/mTOR), we propose an alternative strategy to control oncogenic K-RAS signal by targeting its most downstream signaling module, Seven-In-Absentia Homolog (SIAH). SIAH E3 ligase controls the signal output of oncogenic K-RAS hyperactivation that drives unchecked cell proliferation, uncontrolled tumor growth, and rapid cancer cell dissemination in human pancreatic cancer. Therefore, SIAH is an ideal therapeutic target as it is an extraordinarily conserved downstream signaling gatekeeper indispensable for proper RAS signaling. Guided by molecular insights and core principles obtained from developmental and evolutionary biology, we propose an anti-SIAH-centered anti-K-RAS strategy as a logical and alternative anticancer strategy to dampen uncontrolled K-RAS hyperactivation and halt tumor growth and metastasis in pancreatic cancer. The clinical utility of developing SIAH as both a tumor-specific and therapy-responsive biomarker, as well as a viable anti-K-RAS drug target, is logically simple and conceptually innovative. SIAH clearly constitutes a major tumor vulnerability and K-RAS signaling bottleneck in pancreatic ductal adenocarcinoma (PDAC). Given the high degree of evolutionary conservation in the K-RAS/SIAH signaling pathway, an anti-SIAH-based anti-PDAC therapy will synergize with covalent K-RAS inhibitors and direct K-RAS targeted initiatives to control and eradicate pancreatic cancer in the future.",
keywords = "Evolutionary conservation, Oncogenic K-RAS mutations, Oncogenic K-RAS pathway activation, Oncogenic K-RAS-driven tumor relapse and metastasis, Pancreatic tumor vulnerability, Signaling gatekeeper, SINA and SIAH family of RING domain E3 ligases, Ubiquitin-mediated proteolysis",
author = "{Van Sciver}, {Robert E.} and Lee, {Michael P.} and Lee, {Caroline Dasom} and Lafever, {Alex C.} and Elizaveta Svyatova and Kevin Kanda and Colliver, {Amber L.} and {Siewertsz Van Reesema}, {Lauren L.} and Tang-Tan, {Angela M.} and Vasilena Zheleva and Bwayi, {Monicah N.} and Minglei Bian and Schmidt, {Rebecca L.} and Matrisian, {Lynn M.} and Petersen, {Gloria M} and Tang, {Amy H.}",
year = "2018",
month = "5",
day = "1",
doi = "10.3390/cancers10050142",
language = "English (US)",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - A new strategy to control and eradicate “undruggable” oncogenic K-RAS-driven pancreatic cancer

T2 - Molecular insights and core principles learned from developmental and evolutionary biology

AU - Van Sciver, Robert E.

AU - Lee, Michael P.

AU - Lee, Caroline Dasom

AU - Lafever, Alex C.

AU - Svyatova, Elizaveta

AU - Kanda, Kevin

AU - Colliver, Amber L.

AU - Siewertsz Van Reesema, Lauren L.

AU - Tang-Tan, Angela M.

AU - Zheleva, Vasilena

AU - Bwayi, Monicah N.

AU - Bian, Minglei

AU - Schmidt, Rebecca L.

AU - Matrisian, Lynn M.

AU - Petersen, Gloria M

AU - Tang, Amy H.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Oncogenic K-RAS mutations are found in virtually all pancreatic cancers, making K-RAS one of the most targeted oncoproteins for drug development in cancer therapies. Despite intense research efforts over the past three decades, oncogenic K-RAS has remained largely “undruggable”. Rather than targeting an upstream component of the RAS signaling pathway (i.e., EGFR/HER2) and/or the midstream effector kinases (i.e., RAF/MEK/ERK/PI3K/mTOR), we propose an alternative strategy to control oncogenic K-RAS signal by targeting its most downstream signaling module, Seven-In-Absentia Homolog (SIAH). SIAH E3 ligase controls the signal output of oncogenic K-RAS hyperactivation that drives unchecked cell proliferation, uncontrolled tumor growth, and rapid cancer cell dissemination in human pancreatic cancer. Therefore, SIAH is an ideal therapeutic target as it is an extraordinarily conserved downstream signaling gatekeeper indispensable for proper RAS signaling. Guided by molecular insights and core principles obtained from developmental and evolutionary biology, we propose an anti-SIAH-centered anti-K-RAS strategy as a logical and alternative anticancer strategy to dampen uncontrolled K-RAS hyperactivation and halt tumor growth and metastasis in pancreatic cancer. The clinical utility of developing SIAH as both a tumor-specific and therapy-responsive biomarker, as well as a viable anti-K-RAS drug target, is logically simple and conceptually innovative. SIAH clearly constitutes a major tumor vulnerability and K-RAS signaling bottleneck in pancreatic ductal adenocarcinoma (PDAC). Given the high degree of evolutionary conservation in the K-RAS/SIAH signaling pathway, an anti-SIAH-based anti-PDAC therapy will synergize with covalent K-RAS inhibitors and direct K-RAS targeted initiatives to control and eradicate pancreatic cancer in the future.

AB - Oncogenic K-RAS mutations are found in virtually all pancreatic cancers, making K-RAS one of the most targeted oncoproteins for drug development in cancer therapies. Despite intense research efforts over the past three decades, oncogenic K-RAS has remained largely “undruggable”. Rather than targeting an upstream component of the RAS signaling pathway (i.e., EGFR/HER2) and/or the midstream effector kinases (i.e., RAF/MEK/ERK/PI3K/mTOR), we propose an alternative strategy to control oncogenic K-RAS signal by targeting its most downstream signaling module, Seven-In-Absentia Homolog (SIAH). SIAH E3 ligase controls the signal output of oncogenic K-RAS hyperactivation that drives unchecked cell proliferation, uncontrolled tumor growth, and rapid cancer cell dissemination in human pancreatic cancer. Therefore, SIAH is an ideal therapeutic target as it is an extraordinarily conserved downstream signaling gatekeeper indispensable for proper RAS signaling. Guided by molecular insights and core principles obtained from developmental and evolutionary biology, we propose an anti-SIAH-centered anti-K-RAS strategy as a logical and alternative anticancer strategy to dampen uncontrolled K-RAS hyperactivation and halt tumor growth and metastasis in pancreatic cancer. The clinical utility of developing SIAH as both a tumor-specific and therapy-responsive biomarker, as well as a viable anti-K-RAS drug target, is logically simple and conceptually innovative. SIAH clearly constitutes a major tumor vulnerability and K-RAS signaling bottleneck in pancreatic ductal adenocarcinoma (PDAC). Given the high degree of evolutionary conservation in the K-RAS/SIAH signaling pathway, an anti-SIAH-based anti-PDAC therapy will synergize with covalent K-RAS inhibitors and direct K-RAS targeted initiatives to control and eradicate pancreatic cancer in the future.

KW - Evolutionary conservation

KW - Oncogenic K-RAS mutations

KW - Oncogenic K-RAS pathway activation

KW - Oncogenic K-RAS-driven tumor relapse and metastasis

KW - Pancreatic tumor vulnerability

KW - Signaling gatekeeper

KW - SINA and SIAH family of RING domain E3 ligases

KW - Ubiquitin-mediated proteolysis

UR - http://www.scopus.com/inward/record.url?scp=85047511601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047511601&partnerID=8YFLogxK

U2 - 10.3390/cancers10050142

DO - 10.3390/cancers10050142

M3 - Review article

VL - 10

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 5

M1 - 142

ER -